<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065372</url>
  </required_header>
  <id_info>
    <org_study_id>21-3483</org_study_id>
    <nct_id>NCT05065372</nct_id>
  </id_info>
  <brief_title>MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes</brief_title>
  <acronym>MANATEE-T1D</acronym>
  <official_title>MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and&#xD;
      mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes&#xD;
      and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with&#xD;
      pathophysiology that extends beyond beta-cell injury and insulin deficiency to include&#xD;
      insulin resistance and renal vascular resistance, factors that accelerate cardiovascular&#xD;
      disease risk. We have shown that metformin improved peripheral insulin sensitivity and&#xD;
      vascular stiffness in youth with type 1 diabetes on multiple daily insulin injections or&#xD;
      standard insulin pumps. However, metformin's effect on kidney and endothelial outcomes, and&#xD;
      the effects of type 1 diabetes technologies, with or without metformin, on any cardiovascular&#xD;
      or kidney outcome, remains unknown. Automated insulin delivery systems combine an insulin&#xD;
      pump, continuous glucose monitor, and control algorithm to modulate background insulin&#xD;
      delivery and decrease peripheral insulin exposure while improving time in target range and&#xD;
      reducing hypoglycemia. We hypothesize that automated insulin delivery systems, particularly&#xD;
      when combined with metformin, may modulate renal vascular resistance and insulin sensitivity,&#xD;
      thereby impacting cardiometabolic function. MANATEE-T1D is a randomized, double-blind,&#xD;
      placebo-controlled trial of 4 months of metformin 2,000 mg daily in 40 youth aged 12-21 years&#xD;
      with type 1 diabetes on automated insulin delivery systems vs. 20 control youth with type 1&#xD;
      diabetes on multiple daily injections plus a continuous glucose monitor which will assess for&#xD;
      changes in calculated renal vascular resistance and gold standard measures of whole-body and&#xD;
      adipose insulin sensitivity, arterial stiffness, and endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal vascular resistance</measure>
    <time_frame>4 months</time_frame>
    <description>Renal plasma flow will be measured by para-aminohippurate clearance and used to calculate renal vascular resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>4 months</time_frame>
    <description>Measured by iohexol clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>4 months</time_frame>
    <description>Measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>4 months</time_frame>
    <description>Measured by EndoPAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4 months</time_frame>
    <description>Measured by hyperinsulinemic-euglycemic clamp</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Metformin plus automated insulin delivery system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with metformin and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus automated insulin delivery system</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with a placebo pill which is identical in appearance to the metformin pill and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple daily insulin injections plus continuous glucose monitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with type 1 diabetes using multiple daily injections plus a continuous glucose monitor will not be randomized to receive medication treatment but will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hcl 1000Mg Tab</intervention_name>
    <description>Agent used to modify insulin sensitivity</description>
    <arm_group_label>Metformin plus automated insulin delivery system</arm_group_label>
    <other_name>Fortamet</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminohippurate Sodium 20 % Injection</intervention_name>
    <description>Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance</description>
    <arm_group_label>Metformin plus automated insulin delivery system</arm_group_label>
    <arm_group_label>Multiple daily insulin injections plus continuous glucose monitor</arm_group_label>
    <arm_group_label>Placebo plus automated insulin delivery system</arm_group_label>
    <other_name>Sodium 4-amino hippurate (PAH) injection 20% (2g/10 mL)</other_name>
    <other_name>Para-aminohippurate</other_name>
    <other_name>Aminohippuric acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol 300 Mg/mL Injectable Solution</intervention_name>
    <description>Diagnostic aid/agent used to measure glomerular filtration rate</description>
    <arm_group_label>Metformin plus automated insulin delivery system</arm_group_label>
    <arm_group_label>Multiple daily insulin injections plus continuous glucose monitor</arm_group_label>
    <arm_group_label>Placebo plus automated insulin delivery system</arm_group_label>
    <other_name>Omnipaque 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical to Metformin Hcl 1000Mg Tab but without metabolic effects</description>
    <arm_group_label>Placebo plus automated insulin delivery system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Youth with pancreatic antibody positive type 1 diabetes&#xD;
&#xD;
          -  Age 12-21 years&#xD;
&#xD;
          -  Use of an automated insulin delivery system or multiple daily insulin injections plus&#xD;
             a continuous glucose monitor for &gt; 6 months&#xD;
&#xD;
          -  Pubertal&#xD;
&#xD;
          -  Weight &gt; 54 kg and BMI &gt; 5th percentile for age and sex&#xD;
&#xD;
          -  Hemoglobin A1c &lt; 11%&#xD;
&#xD;
          -  No recent episodes of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar&#xD;
             syndrome (HHS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood pressure &gt; 140/90 mm Hg&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2 or serum creatinine &gt; 1.2&#xD;
             mg/dL or history of urinary albumin to creatinine ratio â‰¥ 300mg/g or history of acute&#xD;
             kidney injury&#xD;
&#xD;
          -  Use of anti-diabetic agents except insulin, angiotensin converting enzyme (ACE)&#xD;
             inhibitors, angiotensin receptor blockers (ARB's), diuretics, daily non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or aspirin, sulfonamides, procaine, thiazosulfone or&#xD;
             probenecid&#xD;
&#xD;
          -  Seafood or iodine allergy&#xD;
&#xD;
          -  Pregnancy or breast feeding for females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucy Hall, MS</last_name>
    <phone>720-777-2692</phone>
    <email>Lucy.Hall@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kalie Tommerdahl, MD</last_name>
    <phone>720-777-5898</phone>
    <email>Kalie.Tommerdahl@childrenscolorado.org</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Youth</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Cardiovascular function</keyword>
  <keyword>Diabetic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

